Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
TABLET, FILM COATED
**Dosage and Administration:** Adults (including the elderly): The recommended adult dosage is 200mg three times a day for as long as required. Children: Not recommended for children under 12 years of age.
ORAL
Medical Information
**Indication(s):** Symptomatic relief of dysuria, urgency, vesical suprapubic pain, nocturia, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis and urethrotrigonitis. Relief of vesico-urethral spasm due to catheterization, cystoscopy or indwelling catheters, prior to cystoscopy or catheterisation, and sequelae of surgical intervention of the lower urinary tract.
**Contraindication(s):** Flavoxate is contraindicated in patients who have hypersensitivity to the active substance or to any of the excipients, gastrointestinal obstructive conditions or ileus, gastrointestinal haemorrhage, achalasia, urinary retention, glaucoma and myasthenia gravis.
G04BD02
flavoxate
Manufacturer Information
YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD
Y.S.P. Industries (M) Sdn. Bhd.
Active Ingredients
Documents
Package Inserts
Uripax Film Coated Tablet PI.pdf
Approved: January 27, 2023